Cargando…

Macrophage-Based Therapies for Atherosclerosis Management

Atherosclerosis (AS), a typical chronic inflammatory vascular disease, is the main pathological basis of ischemic cardio/cerebrovascular disease (CVD). Long-term administration was characterized with low efficacy and serious side effects, while the macrophages with attractive intrinsic homing target...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Renyi, Ji, Hao, Jin, Libo, Lin, Sue, Huang, Yijiang, Xu, Ke, Yang, Qinsi, Sun, Da, Wu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204102/
https://www.ncbi.nlm.nih.gov/pubmed/32411803
http://dx.doi.org/10.1155/2020/8131754
_version_ 1783529993706405888
author Peng, Renyi
Ji, Hao
Jin, Libo
Lin, Sue
Huang, Yijiang
Xu, Ke
Yang, Qinsi
Sun, Da
Wu, Wei
author_facet Peng, Renyi
Ji, Hao
Jin, Libo
Lin, Sue
Huang, Yijiang
Xu, Ke
Yang, Qinsi
Sun, Da
Wu, Wei
author_sort Peng, Renyi
collection PubMed
description Atherosclerosis (AS), a typical chronic inflammatory vascular disease, is the main pathological basis of ischemic cardio/cerebrovascular disease (CVD). Long-term administration was characterized with low efficacy and serious side effects, while the macrophages with attractive intrinsic homing target have great potential in the efficient and safe management of AS. In this review, we focused on the systematical summary of the macrophage-based therapies in AS management, including macrophage autophagy, polarization, targeted delivery, microenvironment-triggered drug release, and macrophage- or macrophage membrane-based drug carrier. In conclusion, macrophage-based therapies have great promise to effectively manage AS in future research and clinic translation.
format Online
Article
Text
id pubmed-7204102
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-72041022020-05-14 Macrophage-Based Therapies for Atherosclerosis Management Peng, Renyi Ji, Hao Jin, Libo Lin, Sue Huang, Yijiang Xu, Ke Yang, Qinsi Sun, Da Wu, Wei J Immunol Res Review Article Atherosclerosis (AS), a typical chronic inflammatory vascular disease, is the main pathological basis of ischemic cardio/cerebrovascular disease (CVD). Long-term administration was characterized with low efficacy and serious side effects, while the macrophages with attractive intrinsic homing target have great potential in the efficient and safe management of AS. In this review, we focused on the systematical summary of the macrophage-based therapies in AS management, including macrophage autophagy, polarization, targeted delivery, microenvironment-triggered drug release, and macrophage- or macrophage membrane-based drug carrier. In conclusion, macrophage-based therapies have great promise to effectively manage AS in future research and clinic translation. Hindawi 2020-01-29 /pmc/articles/PMC7204102/ /pubmed/32411803 http://dx.doi.org/10.1155/2020/8131754 Text en Copyright © 2020 Renyi Peng et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Peng, Renyi
Ji, Hao
Jin, Libo
Lin, Sue
Huang, Yijiang
Xu, Ke
Yang, Qinsi
Sun, Da
Wu, Wei
Macrophage-Based Therapies for Atherosclerosis Management
title Macrophage-Based Therapies for Atherosclerosis Management
title_full Macrophage-Based Therapies for Atherosclerosis Management
title_fullStr Macrophage-Based Therapies for Atherosclerosis Management
title_full_unstemmed Macrophage-Based Therapies for Atherosclerosis Management
title_short Macrophage-Based Therapies for Atherosclerosis Management
title_sort macrophage-based therapies for atherosclerosis management
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204102/
https://www.ncbi.nlm.nih.gov/pubmed/32411803
http://dx.doi.org/10.1155/2020/8131754
work_keys_str_mv AT pengrenyi macrophagebasedtherapiesforatherosclerosismanagement
AT jihao macrophagebasedtherapiesforatherosclerosismanagement
AT jinlibo macrophagebasedtherapiesforatherosclerosismanagement
AT linsue macrophagebasedtherapiesforatherosclerosismanagement
AT huangyijiang macrophagebasedtherapiesforatherosclerosismanagement
AT xuke macrophagebasedtherapiesforatherosclerosismanagement
AT yangqinsi macrophagebasedtherapiesforatherosclerosismanagement
AT sunda macrophagebasedtherapiesforatherosclerosismanagement
AT wuwei macrophagebasedtherapiesforatherosclerosismanagement